Hong Kong · Delayed Price · Currency is HKD Fosun International Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and profit grew strongly in H1 2026, driven by core segments and global expansion. Deleveraging, asset divestments, and innovation—especially in AI and healthcare—remain strategic priorities. Insurance, pharma, and tourism segments delivered robust results.
Fiscal Year 2025
-
Revenue declined 9.7% year-on-year to CNY 173.43 billion, with net profit at -CNY 23.4 billion due to non-cash impairments. Overseas revenue rose to 55% of total, and core subsidiaries showed resilient growth, especially in pharma, insurance, and jewelry.
-
Revenue for H1 2025 was CNY 87.3 billion, with overseas revenue rising to 53%. Profitability remained stable, and key subsidiaries saw strong share price gains. Strategic focus is on globalization, asset-light operations, and technology-driven growth.
Fiscal Year 2024
-
2024 revenue declined 3.1% to CNY 192.1 billion, with a reported net loss due to a non-cash impairment, but adjusted profit was positive. Overseas revenue rose to 49%, and core segments showed stable or growing performance. Strategic focus remains on global expansion, innovation, and asset-light operations.
-
Revenue grew 0.8% year-over-year to RMB 97.8 billion, with overseas revenue up 4% and core subsidiaries contributing 74% of total revenue. Leverage and interest-bearing liabilities were reduced, while asset-light and global expansion strategies remain central to future growth.